$ANIP insider trading
Over the last 12 months, Ani Pharmaceuticals insiders reported no purchases and 35 sales totaling $8.8M across SEC Form 4 filings. 77% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $8.8M 35 events
- Events · 12m
- 35 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 77% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 2,850 | $72.8 | $207K | -1.6% | plan |
| Aug 25, 2026 | Lalwani NikhilPRESIDENT & CEO · O·D | ▼ Sale | 5,400 | $74.3 | $401K | -1.5% | plan |
| Aug 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $75.48 | $38K | -0.7% | plan |
| Aug 10, 2026 | Gutwerg OriSVP, GENERICS · O | ▼ Sale | 3,162 | $77 | $243K | -4% | — |
| Jul 29, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 2,850 | $81.36 | $232K | -1.6% | plan |
| Jul 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $81.84 | $41K | -0.6% | plan |
| Jul 2, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 3,313 | $86 | $285K | -1.8% | plan |
| Jun 29, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 2,850 | $84.12 | $240K | -1.6% | plan |
| Jun 12, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $82.03 | $41K | -0.6% | plan |
| Jun 8, 2026 | HAUGHEY THOMASD | ▼ Sale | 2,000 | $80.88 | $162K | -4.9% | plan |
| Jun 5, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 3,312 | $80 | $265K | -1.8% | plan |
| Apr 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $77.95 | $39K | -0.6% | plan |
| Mar 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $72.62 | $36K | -0.6% | plan |
| Mar 13, 2026 | Mutz ChristopherHEAD OF RARE DISEASE · O | ▼ Sale | 3,162 | $71.64 | $227K | -3.3% | plan |
| Mar 11, 2026 | Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS · O | ▼ Sale | 4,772 | $74.91 | $357K | -11% | — |
| Mar 9, 2026 | Davis KristaSVP, CHIEF HR OFFICER · O | ▼ Sale | 6,572 | $74.33 | $488K | -11.2% | plan · 2 tranches |
| Mar 9, 2026 | Mutz ChristopherHEAD OF RARE DISEASE · O | ▼ Sale | 5,723 | $74.19 | $425K | -5.7% | plan · 2 tranches |
| Mar 5, 2026 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 7,312 | $75.5 | $552K | -3.8% | 2 tranches |
| Mar 3, 2026 | Gutwerg OriSVP, GENERICS · O | ▼ Sale | 2,060 | $76.5 | $158K | -2.4% | — |
| Mar 3, 2026 | Walsh Patrick DD | ▼ Sale | 6,000 | $74.23 | $445K | -10.3% | — |
| Mar 2, 2026 | Mutz ChristopherHEAD OF RARE DISEASE · O | ▼ Sale | 417 | $74 | $31K | -0.4% | plan |
| Feb 20, 2026 | Davis KristaSVP, CHIEF HR OFFICER · O | ▼ Sale | 3,814 | $77.74 | $296K | -7.2% | plan · 2 tranches |
| Feb 20, 2026 | Mutz ChristopherHEAD OF RARE DISEASE · O | ▼ Sale | 5,323 | $78.02 | $415K | -5.9% | plan |
| Feb 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $76.8 | $38K | -0.7% | plan |
| Feb 12, 2026 | Mutz ChristopherHEAD OF RARE DISEASE · O | ▼ Sale | 7,032 | $76.55 | $538K | -7.1% | plan |
| Jan 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 500 | $84.33 | $42K | -0.7% | plan |
| Dec 18, 2025 | Davis KristaSVP, CHIEF HR OFFICER · O | ▼ Sale | 1,622 | $82.4 | $134K | -2.7% | plan |
| Dec 12, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 400 | $82.32 | $33K | -0.5% | plan |
| Dec 5, 2025 | TANNENBAUM RENEE PD | ▼ Sale | 1,800 | $81.15 | $146K | -6.7% | — |
| Nov 13, 2025 | Walsh Patrick DD | ▼ Sale | 8,643 | $86.88 | $751K | -12.3% | — |
| Nov 13, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 400 | $87.27 | $35K | -0.5% | plan |
| Nov 13, 2025 | Gassert ChadSVP - CORP. DEV. & STRATEGY · O | ▼ Sale | 14,736 | $89.06 | $1.3M | -8.5% | 2 tranches · indirect |
| Oct 13, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 400 | $90.09 | $36K | -0.5% | plan |
| Sep 19, 2025 | Davis KristaSVP, CHIEF HR OFFICER · O | ▼ Sale | 1,000 | $98.04 | $98K | -1.6% | plan |
| Sep 12, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 400 | $98.42 | $39K | -0.5% | plan |
| Sep 3, 2025 | Pera Antonio RD | ▼ Sale | 7,292 | $94.94 | $692K | -24.3% | — |
| Aug 25, 2025 | Leonard Matthew JD | ▼ Sale | 2,528 | $90.62 | $229K | -26.9% | — |
| Aug 22, 2025 | Davis KristaSVP, CHIEF HR OFFICER · O | ▼ Sale | 1,763 | $91.1 | $161K | -2.7% | — |
| Aug 21, 2025 | Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS · O·D | ▼ Sale | 100,000 | $90.36 | $9.0M | -18.8% | 2 tranches · indirect |
| Aug 20, 2025 | Pera Antonio RD | ▼ Sale | 5,421 | $89.73 | $486K | -15.3% | — |
| Aug 18, 2025 | Thoma JeanneD | ▼ Sale | 21,540 | $89.15 | $1.9M | -47.9% | 2 tranches |
| Aug 18, 2025 | Leonard Matthew JD | ▼ Sale | 6,937 | $88.17 | $612K | -42.5% | — |
| Aug 15, 2025 | Gassert ChadSVP - CORP. DEV. & STRATEGY · O | ▼ Sale | 20,000 | $86.97 | $1.7M | -10.4% | indirect |
| Aug 15, 2025 | Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS · O·D | ▼ Sale | 100,000 | $88.25 | $8.8M | -15.8% | 2 tranches · indirect |
| Aug 15, 2025 | Walsh Patrick DD | ▼ Sale | 9,000 | $89.05 | $801K | -11.4% | — |
| Aug 13, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · O | ▼ Sale | 400 | $88.87 | $36K | -0.5% | plan |
| Aug 12, 2025 | Gutwerg OriSVP, GENERICS · O | ▼ Sale | 5,873 | $86.53 | $508K | -6.5% | — |
| Aug 12, 2025 | Lalwani NikhilPRESIDENT & CEO · O·D | ▼ Sale | 56,960 | $85.93 | $4.9M | -12.2% | — |
| Aug 12, 2025 | CAREY STEPHEN P.SVP & CFO · O | ▼ Sale | 50,000 | $86.07 | $4.3M | -21.7% | — |
| Aug 12, 2025 | Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS · O | ▼ Sale | 4,975 | $85.71 | $426K | -10.9% | — |
Every $ANIP filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ani Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ANIP feed.